Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Allison Dorval sold 11,610 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $83,592.00. Following the transaction, the director owned 90,780 shares in the company, valued at $653,616. The trade was a 11.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Puma Biotechnology Trading Down 3.5%
PBYI stock traded down $0.26 during trading hours on Monday, hitting $7.07. 177,368 shares of the stock were exchanged, compared to its average volume of 189,537. The firm has a market capitalization of $359.86 million, a P/E ratio of 14.73 and a beta of 1.21. The company has a 50-day simple moving average of $7.23 and a two-hundred day simple moving average of $6.57. Puma Biotechnology, Inc. has a 12 month low of $3.03 and a 12 month high of $7.90.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $44.81 million for the quarter, compared to analysts’ expectations of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. On average, equities research analysts predict that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research analysts recently commented on PBYI shares. Weiss Ratings cut Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Puma Biotechnology currently has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on PBYI
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Read More
- Five stocks we like better than Puma Biotechnology
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
